UY36654A - Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen - Google Patents

Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen

Info

Publication number
UY36654A
UY36654A UY0001036654A UY36654A UY36654A UY 36654 A UY36654 A UY 36654A UY 0001036654 A UY0001036654 A UY 0001036654A UY 36654 A UY36654 A UY 36654A UY 36654 A UY36654 A UY 36654A
Authority
UY
Uruguay
Prior art keywords
pharmaceutical compositions
azabenzimidazoles
compositions containing
ampa receptor
receptor modulating
Prior art date
Application number
UY0001036654A
Other languages
English (en)
Inventor
Michael K Ameriks
Cyntha G B Berry
Jourdan Fabrice Loic
Lebold Terry Patrick
Lin David Wei
Pena Piñon Miguel Angel
Ravula Suchitra
Devin M Swanson
Wu Dongpei
Zhang Wei
Chen Gang
Bradley M Savall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY36654A publication Critical patent/UY36654A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Abstract

En la presente invención se proporcionan compuestos de la Fórmula (I) y sales farmacéuticamente aceptables, N-óxidos o solvatos de estos.Además, se proporcionan en la presente invención composiciones farmacéuticas que comprenden compuestos de la Fórmula (I) y métodos para usar los compuestos de la Fórmula (I).
UY0001036654A 2015-04-29 2016-04-28 Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen UY36654A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
UY36654A true UY36654A (es) 2016-10-31

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036654A UY36654A (es) 2015-04-29 2016-04-28 Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen

Country Status (39)

Country Link
US (4) US11312712B2 (es)
EP (3) EP4144736A1 (es)
JP (2) JP6800886B2 (es)
KR (2) KR20240017991A (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR112017023147A2 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HK (1) HK1252249A1 (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX2017013886A (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816A1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984307A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
US11447488B2 (en) 2017-10-06 2022-09-20 Takeda Pharmaceutical Company Limited Heterocyclic compounds
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
CN113454080A (zh) * 2018-10-30 2021-09-28 修复治疗公司 化合物、药物组合物和制备化合物的方法以及其使用方法
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
KR970701182A (ko) 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
EP1139754A4 (en) 1998-12-31 2002-12-18 Sugen Inc 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATION OF PROTEIN KINASE ACTIVITY AND IN CANCER CHEMOTHERAPY
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
AU2001282865A1 (en) 2000-08-11 2002-02-25 Eli Lilly And Company Heterocyclic sulfonamide derivatives
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP5209311B2 (ja) * 2004-09-03 2013-06-12 メルク セローノ ソシエテ アノニム ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
DE602006019119D1 (de) 2005-09-30 2011-02-03 Glaxo Group Ltd Verbindungen mit aktivität am m1-rezeptor und ihre verwendung in der medizin
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
WO2008053031A1 (en) 2006-11-03 2008-05-08 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
US8450343B2 (en) * 2007-12-06 2013-05-28 Xianhai Huang Gamma secretase modulators
TW201012803A (en) * 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
WO2010005528A2 (en) * 2008-06-30 2010-01-14 Ironwood Pharmaceuticals Incorporated Pyrrolopyridine carboxylic acid derivatives
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
AU2011290126B2 (en) 2010-08-10 2016-01-07 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2603079B1 (en) 2010-08-12 2018-09-19 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
WO2013130501A1 (en) * 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios

Also Published As

Publication number Publication date
DK3288940T5 (da) 2021-09-20
KR20170140382A (ko) 2017-12-20
AU2016255434A1 (en) 2017-10-26
JO3654B1 (ar) 2020-08-27
US20210284641A1 (en) 2021-09-16
MA41988A (fr) 2018-07-03
AR104447A1 (es) 2017-07-19
DK3288940T3 (da) 2021-05-25
UA120304C2 (uk) 2019-11-11
GT201700231A (es) 2018-12-20
AU2016255434B2 (en) 2020-05-14
TWI706952B (zh) 2020-10-11
US11312712B2 (en) 2022-04-26
BR112017023147A2 (pt) 2018-07-10
AU2016255434C1 (en) 2021-09-23
IL254848A0 (en) 2017-12-31
TW201708217A (zh) 2017-03-01
WO2016176460A1 (en) 2016-11-03
CA2983826A1 (en) 2016-11-03
NI201700129A (es) 2019-05-10
EP3288940B9 (en) 2021-07-21
PH12017501816A1 (en) 2018-04-23
PL3288940T3 (pl) 2021-07-12
MY194104A (en) 2022-11-11
CN107835814B (zh) 2021-07-23
HRP20210403T1 (hr) 2021-10-29
ZA201708065B (en) 2019-09-25
US20180118740A1 (en) 2018-05-03
RS61688B1 (sr) 2021-05-31
EA033281B1 (ru) 2019-09-30
HK1252249A1 (zh) 2019-05-24
JP2018518462A (ja) 2018-07-12
JP6800886B2 (ja) 2020-12-16
JP7026194B2 (ja) 2022-02-25
ES2865330T3 (es) 2021-10-15
US20230110576A1 (en) 2023-04-13
US20230114165A1 (en) 2023-04-13
BR122023023802A2 (pt) 2023-12-26
EA201792374A1 (ru) 2018-05-31
NZ736057A (en) 2023-08-25
MA41988B1 (fr) 2021-03-31
MX2017013886A (es) 2018-03-12
EP3288940B1 (en) 2021-02-24
AU2020210231B2 (en) 2021-07-22
ECSP17074645A (es) 2018-02-28
SI3288940T1 (sl) 2021-07-30
CR20170484A (es) 2018-02-26
JP2021042230A (ja) 2021-03-18
IL254848B (en) 2021-01-31
KR20240017991A (ko) 2024-02-08
AU2020210231A1 (en) 2020-08-20
SG11201708190UA (en) 2017-11-29
EP3901153A1 (en) 2021-10-27
EP4144736A1 (en) 2023-03-08
CY1124059T1 (el) 2022-05-27
CN107835814A (zh) 2018-03-23
MD3288940T2 (ro) 2021-08-31
EP3288940A1 (en) 2018-03-07
HUE053943T2 (hu) 2021-08-30
LT3288940T (lt) 2021-05-10
PT3288940T (pt) 2021-04-30
CO2017011017A2 (es) 2018-03-20

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
DOP2017000151A (es) Derivados de quinazolina utilizados para tratar el vih
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201791304A1 (ru) Производные изохинолина для лечения вич
ECSP16074478A (es) Compuestos novedosos
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
ECSP17069696A (es) Compuestos novedosos
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
TR201819805T4 (tr) Flavaglin türevleri̇.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores